These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1044 related items for PubMed ID: 31416644

  • 21. Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.
    Palomo C, Mas V, Thom M, Vázquez M, Cano O, Terrón MC, Luque D, Taylor G, Melero JA.
    J Virol; 2016 Jun 01; 90(11):5485-5498. PubMed ID: 27009962
    [Abstract] [Full Text] [Related]

  • 22. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B, Matsuoka Y, Le Nouën C, Liu X, Herbert R, Swerczek J, Santos C, Paneru M, Collins PL, Buchholz UJ, Munir S.
    J Virol; 2020 Dec 22; 95(2):. PubMed ID: 33115876
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R, Brownlie R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.
    Antiviral Res; 2018 Oct 22; 158():78-87. PubMed ID: 30071204
    [Abstract] [Full Text] [Related]

  • 26. The Respiratory Syncytial Virus (RSV) G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-Like Particle Vaccine Candidate.
    McGinnes Cullen L, Luo B, Wen Z, Zhang L, Durr E, Morrison TG.
    J Virol; 2023 Jan 31; 97(1):e0190022. PubMed ID: 36602367
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
    Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A.
    J Virol; 2014 May 31; 88(9):5100-8. PubMed ID: 24574396
    [Abstract] [Full Text] [Related]

  • 30. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS, Kim KH, Lee Y, Lee YT, Ko EJ, Park S, Lee JS, Lee BC, Kwon YM, Moore ML, Kang SM.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1031-1039. PubMed ID: 28129031
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Potent Human Single-Domain Antibodies Specific for a Novel Prefusion Epitope of Respiratory Syncytial Virus F Glycoprotein.
    Xun G, Song X, Hu J, Zhang H, Liu L, Zhang Z, Gong R.
    J Virol; 2021 Aug 25; 95(18):e0048521. PubMed ID: 34160257
    [Abstract] [Full Text] [Related]

  • 34. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K, Bastian AR, Feldman RA, Omoruyi E, de Paepe E, Hendriks J, van Zeeburg H, Godeaux O, Langedijk JPM, Schuitemaker H, Sadoff J, Callendret B.
    J Infect Dis; 2020 Aug 17; 222(6):979-988. PubMed ID: 32320465
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.